Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06569472 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis

StatusRecruiting
PhasePhase 1
Started2024-07-02
View on ClinicalTrials.gov ↗
This is a Phase I clinical trial to evaluate the efficacy and safety of CD19-targeted CAR-T in the treatment of refractory juvenile dermatomyositis (RJDM).The experiment was divided into two phases: dose exploration (Part A) and dose extension (Part B).
Trial Details
NCT Number NCT06569472
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Conditions Juvenile Dermatomyositis
Enrollment 10 participants
Start Date 2024-07-02
Primary Completion 2027-07-31 (estimated)
Study Completion 2028-07-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-26